Background: Chronic hepatitis B (CHB) cannot be completely eradicated due to the presence of covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes. While quantification of intrahepatic cccDNA requires liver biopsies, serological markers can be non-invasive alternatives to reflect intrahepatic viral replicative activity. Recently, hepatitis B core-related antigen (HBcrAg) has been advocated as a novel serum marker for disease monitoring and prognostication of CHB.
| INTRODUCTION
Chronic hepatitis B (CHB) affects approximately 240 million persons worldwide, 1 with an estimated 15%-40% progressing to cirrhosis, decompensation and/or hepatocellular carcinoma (HCC). 2 Currently, hepatitis B virus (HBV) cannot be completely eradicated due to the presence of covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes. [3] [4] [5] Therefore, the present goal of monitoring is to ensure a high degree of virological suppression, ideally with hepatitis B surface antigen (HBsAg) seroclearance, leading to biochemical remission, histological improvement and reduction of the risk of complications. 6, 7 Although liver biopsy for the quantification of intrahepatic cccDNA and intrahepatic HBV DNA remains the most accurate measurement for viral reservoir, it is limited by its invasive nature, the potential for sampling error and the lack of a standardised assay. Noninvasive serological markers can be used as surrogate markers of intrahepatic viral replicative activity. Established serological markers include serum HBV DNA levels and serum HBsAg titres, both of which have been shown to predict the risk of cirrhosis and HCC. [8] [9] [10] [11] However, as cirrhosis and HCC can still occur in many patients despite undetectable HBV DNA 12 and HBsAg seroclearance, 13, 14 any promising markers with predictive value in these scenarios are very much welcome. Moreover, given that almost all patients treated with antiviral therapy have undetectable HBV DNA, more accurate biomarkers for risk stratification are needed. Recently, linearised HBsAg (HQHBsAg) assay achieving an even lower limit of detection for HBsAg 15 has been shown to correlate with serum HBV DNA and HBsAg levels, which makes it a potential marker for stratifying patients with HBsAg seroclearance. 16 Another new marker, the hepatitis B core-related antigen (HBcrAg), has also been advocated as a serum marker for disease monitoring and prognostication of CHB. In this review, the clinical application of HBcrAg in CHB patients based on its virological features, the distinctive profiles in different disease stages and the profile under anti-viral treatment will be discussed.
| HBV REPLICATION
After initial viral entry into the infected hepatocyte and formation of stable cccDNA minichromosomes in the nucleus, the first step of HBV replication starts with HBV transcription. Five major messenger RNAs (mRNAs) species, namely the core mRNA/pregenomic RNA (3.5 kb), precore mRNA (3.5 kb), LHBs mRNA (2.4 kb), MHBs and SHBs mRNA (2.1 kb) and X mRNA (0.9 kb), are generated from the minus strand of the genome. These mRNAs encode for various structural and non- is also a processed product of the precore protein, but with protein processing at both the N-and C-terminals. 17 The viral replication cycle and the origins of HBV DNA, HBsAg, HBeAg and HBcrAg are illustrated in Figure 1 .
| HBcrAg MEASUREMEN T
The first prototype HBcrAg assay was reported in 2002. 18 As HBcAg, HBeAg and p22cr all share an identical 149 amino acid sequence, the same monoclonal antibodies can be used for the detection of all 3 proteins. The specimen is mixed with anti-HBcrAg-coated particles and allowed to form antigen-antibody immunocomplexes. Alkalaine phosphatase (ALP)-labelled anti-HBcrAg specifically binds to HBcrAg of the immunocomplexes on the particles, and additional immunocomplexes are formed. Luminescence is generated and the luminescent signal reflects the amount of HBcrAg. Quantitation of HBcrAg is made by comparing the chemiluminescence signal generated by known concentration of recombinant ProHBeAg. This assay is currently available in an automated format, using the Lumipulse G1200 CLEIA analyser (Fujirebio, Tokyo, Japan), with a lower limit of detection of 2.0 log U/mL, and a linear range of 3.0 log U/mL-7.0 log U/mL (1 kU/mL is equal to 3 logU/mL). Samples with HBcrAg above 7 log U/mL can be diluted and retested in order to calculate the quantitative HBcrAg level.
According to the Lumipulse â G HBcrAg Immunoreaction cartridges set product insert, the accuracy of the test is confirmed by assay values (calculated with the assay values in log U/mL) for 3 in-house controls range within AE 5% of their control values. The coefficient of variation for specimens (calculated with the assay values in log U/mL) is less than 5% when subjected to the assay 6 replicates. The analytical sensitivity of the reagent is 3.0 logU/mL. Serum-plasma equivalence is reflected by correlation coefficient of 0.999. 
| CORRELATION WITH EXISTING

| Intrahepatic cccDNA
It has been shown that serum cccDNA levels correlated only moderately (r = .481) with intrahepatic cccDNA (N = 39) and the assay involves multiple complicated steps 23 rendering it an unfavourable surrogate marker. HBcrAg has a much stronger correlation with intrahepatic cccDNA. 21, 22, 24 Except for a study with small number of patients (N = 31) 24 , the correlation coefficient is .664-.70 (Table 3) . 21, 22 In comparison, serum HBV DNA also correlates equally well with intrahepatic cccDNA (correlation coefficient .7, P<.001). 22 However, patients receiving anti-viral therapy often have undetectable serum HBV DNA, while 78% of these patients still have detectable serum
HBcrAg. 22 Therefore, in the context of serum DNA undetectability, HBcrAg would be the preferred serum marker to estimate intrahepatic cccDNA quantity. 
| PROFILE OF H BcrAg IN THE NATURAL HISTORY OF CHB
In the natural history of CHB infection, HBcrAg levels change significantly during the 4 phases of CHB infection. The profiles were well characterised by 2 landmark studies performed in treatment-na€ ıve Asian (N = 404) and European (N = 249) CHB patients across genotypes A-D. 16, 26 In both studies, the HBcrAg levels differed significantly between HBeAg-positive and -negative patients. In general, HBeAg-positive patients have a higher HBcrAg level compared to HBeAg-negative patients ( Figure 2 ). This is related to the diminished production of HBeAg after HBeAg seroconversion. Specifically, in
HBeAg-positive patients, the HBcrAg levels were 8.54 and 7.92 log U/mL in HBeAg-positive chronic infection (also known as immunotolerant phase) and HBeAg-positive chronic hepatitis (also known as immune clearance phase) respectively (P<.001). 16 It suggests that HBeAg-positive patients with lower HBcrAg levels are more likely to be under a more intense immune control. Therefore, whether HBcrAg levels can reflect immune clearance activity deserves more future studies to examine.
For HBeAg-negative patients, the HBcrAg levels were significantly lower in HBeAg-negative chronic infection (also known as inactive carrier state) patients compared to HBeAg-negative chronic hepatitis (also known as HBeAg-negative active phase) patients (2.60 vs 4.92 log U/mL, respectively; P<.001) ( Figure 2 ). 16 A higher
HBcrAg in HBeAg-negative chronic hepatitis compared to HBeAgnegative chronic infection was associated with more significant necroinflammatory activity and significant fibrosis. 27 Unlike in
HBeAg-positive phase, if HBeAg-negative patients (although with lower HBcrAg level compared with HBeAg-positive patients) still have relatively high HBcrAg levels after HBeAg seroconversion, the disease activities are in fact more advanced.
For patients who underwent spontaneous HBsAg seroclearance, most of them (79%) had undetectable HBcrAg levels signifying a more quiescent disease state. Of the 21% still having detectable HBcrAg in the serum, the median HBcrAg was 2.7 log U/mL. 16, 28 All of the above findings offer a potential role for HBcrAg to further define the phases of CHB infection, although the optimal cutoffs remain to be determined. The latest EASL guideline acknowledged the potential of HBcrAg to help define the phase of chronic HBV infection, especially in HBeAg-negative patients. respectively. 35 Whether HBcrAg levels can be predictive of spontaneous HBsAg seroclearance remains to be determined.
| HBcrAg AND ANTI-VIRAL THERAPY
Despite achieving an undetectable serum HBV DNA during anti-viral therapy, the majority will still have persistent infection. 4, 23, 36 In a study of 43 patients treated with NA for a median of 126 months, 98% had undetectable serum HBV DNA, while 51% still had detectable intrahepatic cccDNA. 37 Similar findings were reported in 24 patients treated with sequential therapy of pegylated interferon (PEG-IFN) and adefovir (ADV) followed by ADV monotherapy, with 46% and 66% having undetectable serum HBV DNA and detectable intrahepatic cccDNA respectively. 38 Therefore, a decline in serum HBV DNA does not correlate well with a reduction in intrahepatic cccDNA for those receiving anti-viral therapy. In contrast, HBcrAg levels decline in a similar manner as cccDNA when patients are treated with NA (Table 4) . 21 In patients treated with entecavir (ETV), the annual rate of HBcrAg decline was shown to be 0.244 kU/mL/year after 7 years of treatment. 39 More rapid decline was seen in patients who were HBeAg positive, had high baseline HBV DNA, and in the first year of ETV therapy compared to subsequent years ( Figure 3) . 39 More importantly, the decline in HBcrAg demonstrates good correlation with the magnitude of change in intrahepatic cccDNA. 21, 22 For patients treated with up to 5 years of ETV, there was a significant correlation, although moderately, between the decline of serum HBcrAg and intrahepatic cccDNA (r = .419, P = .005). 40 In contrast to serum HBV DNA, the decline in HBcrAg was slower during NA exposure, 41 with an increment in the ratio of serum HBcrAg:HBV DNA after 3 months of lamivudine (LAM). 20 The divergence between the 2 can be explained by the action of NA on reverse transcription and subsequent prevention of HBV DNA replication, while HBcrAg production remains unaffected. Therefore, it is not surprising that in NA-treated patients with undetectable serum HBV DNA, 78% had persistence of HBcrAg. 22 Even in patients with Maasoumy et al. *26 Lower limit of detection: 2 log U/mL (Table 5 ). 43 The number of patients in these 2 studies were too small (N = 58 and 8 respectively) to demonstrate any specific pattern of HBcrAg levels during PEG-IFN therapy.
The profile of HBcrAg was further described in 58 CHB patients due to deaths in nonhuman primates receiving doses higher than those used in human subjects, the initial findings suggested that interfering with RNA transcription reduced the antigen production driven by cccDNA in HBeAg-positive patients. 44 These studies demonstrated that HBcrAg is a responsive viral marker to be measured whenever treatment can suppress viral DNA and protein synthesis. In particular for a situation where serum HBV DNA becomes undetectable, HBcrAg seems to remain as a measurable serum marker to correlate with the cccDNA.
Baseline and changes in HBcrAg levels while on anti-viral therapy may also predict useful milestones in CHB patients. For patients treated with PEG-IFN, a baseline high HBcrAg level >8 log U/mL would confer >94.4% NPV for achieving HBeAg seroconversion and suppressed HBV DNA at 12 weeks (N = 46). 45 In another study of 50 patients receiving sequential therapy of PEG-IFN plus NA for 4 weeks followed by PEG-IFN for 20 weeks, a high HBcrAg level (>4.5 log U/mL) at initiation of therapy predicted nonresponse and no HBeAg seroconversion at 24 months after completion of treatment. 46 Furthermore, the on-treatment changes in HBcrAg levels may be useful to predict clinical outcomes. In 58 patients treated with PEG-IFN, the HBcrAg at week 12 of therapy was predictive of HBeAg seroconversion at 24 weeks after completion of therapy with AUROC of 0.896. 42 For patients treated with NA therapy (N = 39), the HBcrAg levels were shown to be lower in patients with NA-induced HBeAg seroconversion compared to those who remained HBeAg-positive. 21 Studies have also reported on the use of HBcrAg in predicting HBsAg seroclearance, although the findings remain inconclusive. In a study of 62 HBeAg-negative CHB patients, the NPVs for achieving HBsAg loss were 79% and 89% for HBeAg-negative patients with baseline HBcrAg >3.7 log U/mL receiving PEG-IFN alone or in combination with tenofovir-disoproxil-fumarate (TDF) respectively. 47 The AUROC for HBsAg loss was 0.763 if both mean baseline HBcrAg plus HBsAg were used to predict HBsAg loss, although this 43 FU, follow-up; HBcrAg, hepatitis B core-related antigen; PEG-IFN, pegylated interferon.
performed no better than using HBsAg titre alone (AUROC 0.771). 48 It seems that HBcrAg may not be more advantageous than HBsAg titre in terms of predicting HBsAg loss in treatment-experienced patients.
Although the majority of patients treated with NA will remain on long-term therapy, a proportion of patients may opt to discontinue therapy. The decision to stop therapy has been traditionally based on viral serological markers, serum HBV DNA, ALT and more recently, HBsAg levels. The decline in HBcrAg observed under treatment with NA therapy, and the pattern of decline, might provide prognostic information on the risk of post-treatment reactivation of HBV. 43 For patients treated with LAM or ETV, a high end-of-treatment HBcrAg levels (reported range: 3.2-3.7 log U/mL) was shown to predict relapse after cessation of therapy despite undetectable HBV DNA for at least 6 months (Table 6) . [49] [50] [51] [52] Another study
showed that an end-of-treatment HBcrAg level >3.7 log IU/mL predicted virological relapse within 1 year of cessation of NA. 52 Therefore, additional markers such as HBcrAg may better risk-stratify patients that are contemplating cessation of NA. The Japanese Society of Hepatology guidelines have recently incorporated the use of HBcrAg levels in identifying patients at low risk of relapse using the cut-offs <1.9 log U/mL or <3.0 log U/mL for HBsAg and HBcrAg respectively. 53 Validation studies using these criteria for selecting patients to stop NA should be performed in different populations. treatment-na€ ıve patients, the time-dependent AUROCs of HBcrAg for predicting HCC incidence were superior to HBV DNA levels for up to 10 years of follow-up. 64 For treatment-experienced patients, NA can only reduce but cannot eliminate the risk of HCC, 65 and HBcrAg positivity after NA for at least 2-year duration was an independent risk factor for HCC. 62 In 76 CHB patients treated with NA with undetectable serum HBV DNA, the pre-treatment HBcrAg levels were significantly higher in the HCC group compared to the matched control group (279.0 vs 35.4 kU/mL, ie 5.45 log U/mL vs 4.55 log U/mL respectively; P = .005) and a pre-treatment cut-off of 47.1 kU/mL (ie 4.67 log U/mL) independently predicted HCC. Furthermore, a posttreatment HBcrAg >7.8 kU/mL (ie 3.89 log U/mL) predicted HCC with an odds ratio of 3.27. When only noncirrhotic patients were considered, a cut-off of >7.9 kU/mL (ie 3.90 log U/mL) predicted HCC with an odds ratio of 5.95. 66 These findings highlight the importance of conducting further studies to examine the predictive capacity of using 
| HBcrAg AND LIVER TRANSPLANTATION
Although LT is curative for cirrhosis and HCC, it does not completely eradicate HBV due to extra-hepatic reservoirs, and lifelong anti-viral prophylaxis is required. [81] [82] [83] [84] [85] Therefore, the goal of antiviral therapy in this setting is to prevent recurrence of graft hepatitis, rather than re-infection as the patients are already chronically infected. [86] [87] [88] The role of HBcrAg in post-LT patients remains to be determined. In a study of 11 patients with pre-LT positive serum HBcrAg, 6 of them still had detectable serum HBcrAg at 6 months post-operatively, although at lower levels (pre-LT: 5.25 log U/mL vs post-LT: 2.87 log U/mL). In all the 6 patients, serum
HBsAg and HBV DNA remained negative and none of them had elevated ALT. Similar findings were reported by another study of 32 post-LT patients, which showed that 50% remained positive for HBcrAg even though only 18.8% had reappearance of HBV DNA and/or serum HBsAg. 74 There was a correlation between
HBcrAg and cccDNA in the liver grafts (r = .616, P<.001) and higher histological stages of liver fibrosis were observed in patients with detectable serum HBcrAg and positive intrahepatic cccDNA. 
| UNR ESOLVE D ISSUES OF H BcrAg
There are several unresolved issues in HBcrAg measurement.
Firstly, the lower limit of detection for serum HBcrAg is 2 logU/ mL, and this is particularly an issue for HBeAg-negative patients.
Up to 42% patients with HBeAg-negative chronic infection had 
